Premium
Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen
Author(s) -
Zhu Yunshan,
Yang Jianhua
Publication year - 2013
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.12072
Subject(s) - medicine , tamoxifen , endometrial cancer , breast cancer , endometrium , adjuvant , endometrial polyp , uterine cancer , endometrial ablation , postmenopausal women , gynecology , oncology , urology , cancer , ablation
Aim The purpose of the current study was to determine the effectiveness of microwave endometrial ablation ( MEA ) in inhibiting the proliferative response of the endometrium in women with breast cancer who are treated with tamoxifen. Material and Methods In the before–after study, we treated 31 postmenopausal patients who had received adjuvant tamoxifen for 1 year or more with MEA , the endometrial changes were compared before and after MEA . Results After MEA , the thickness of the uterine lining was decreased significantly. No patient had recurrent endometrial polyps or abnormal vaginal bleeding during the follow‐up period. Conclusion MEA had a protective action against the uterine effects of tamoxifen for postmenopausal patients. MEA is a safe and effective minimally invasive treatment method for breast cancer patients treated with tamoxifen.